Companies invest in Avraham to pursue phase IIb ladostigil trial in Alzheimer's disease April 16, 2010
Swedish Orphan Biovitrum receives distribution rights to Rhucin in agreement with Pharming April 16, 2010
Catalyst signs agreement with NIDA for phase IIb vigabatrin trial for cocaine addiction April 15, 2010